Treatment of Helicobacter pylori infection

Helicobacter

Volumn 13, Issue SUPPL.1, 2008, Pages 35-40

  Egan, Brian J ^a   Marzio, Leonardo ^b   O'Connor, Humphrey ^a   O'Morain, Colm ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Antibiotic resistance; Quadruple therapy; Sequential therapy; Triple therapy; Vaccine

Indexed keywords

ACETAZOLAMIDE; AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; ESOMEPRAZOLE; ETHOXZOLAMIDE; HELICOBACTER PYLORI VACCINE; LACTOFERRIN; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; PSEUDOMONIC ACID; PYLORICIDIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE BISMUTH CITRATE; RIFABUTIN; RIFAMPICIN; SITAFLOXACIN; SULFONAMIDE; SULPIRIDE; TETRACYCLINE; THIENYLTHIAZOLE DERIVATIVE; TINIDAZOLE; TOPIRAMATE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BIFIDOBACTERIUM; CLINICAL TRIAL; DOSE RESPONSE; DRUG TARGETING; ERADICATION THERAPY; GENOMICS; GYNECOLOGIC INFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LACTOBACILLUS; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

EID: 49249136450     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2008.00639.x     Document Type: Article

References (48)

1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 : 772 81.
2. Furuta T, Soya Y, Sugimoto M et al. Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin. J Gastroenterol Hepatol 2007 22 : 1810 5.
3. Noguchi N, Rimbara E, Kato A, Tanaka A, Tokunaga K, Kawai T, Takahashi S, Sasatsu M. Detection of mixed clarithromycin-resistant and -susceptible Helicobacter pylori using nested PCR and direct sequencing of DNA extracted from faeces. J Med Microbiol 2007 56 : 1174 80.
4. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, Soussy CJ, Cambau E. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007 29 : 389 96.
5. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, Vaira D. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 2007 25 : 1429 34.
6. Chisholm SA, Teare EL, Davies K, Owen RJ. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-05). Euro Surveill 2007 12 : E3 4.
7. Kalach N, Serhal L, Asmar E et al. Helicobacter pylori primary resistant strains over 11 years in French children. Diagn Microbiol Infect Dis 2007 59 : 217 22.
8. Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis 2008 60 : 409 15.
9. Rafeey M, Ghotaslou R, Nikvash S, Hafez AA. Primary resistance in Helicobacter pylori isolated in children from Iran. J Infect Chemother 2007 13 : 291 5.
10. Aboderin OA, Abdu AR, Odetoyin B, Okeke IN, Lawal OO, Ndububa DA, Agbakwuru AE, Lamikanra A. Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west, Nigeria. Afr Health Sci 2007 7 : 143 7.
11. Fariña N, Kasamatsu E, Samudio M, Morán M, Sanabria R, Laspina F. Antimicrobial susceptibility of H. pylori strains obtained from Paraguayan patients. Rev Med Chil 2007 135 : 1009 14.
12. Lee CC, Lee VW, Chan FK, Ling TK. Levofloxacin-resistant Helicobacter pylori in Hong Kong. Chemotherapy 2008 54 : 50 3.
13. Kobayashi I, Murakami K, Kato M et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007 45 : 4006 10.
14. Bang SY, Han DS, Eun CS, Kim JE, Ahn SB, Sohn JH, Jeon YC, Kang JO. Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease. Korean J Gastroenterol 2007 50 : 356 62.
15. Hu CT, Wu CC, Lin CY, Cheng CC, Su SC, Tseng YH, Lin NT. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J Gastroenterol Hepatol 2007 22 : 720 3.
16. Calvet X, Garcia N, Lopez T et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000 14 : 603 9.
17. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007 102 : 1808 25.
18. Choi WH, Park DI, Oh SJ et al. Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea. Korean J Gastroenterol 2008 51 : 280 4.
19. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008 19.
20. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007 146 : 556 63.
21. Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol 2006 20 : 113 7.
22. Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, Cavina M, Ierardi E, Morini S, Vaira D. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther 2005 21 : 1419 24.
23. De Francesco V, Zullo A, Hassan C et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis 2004 36 : 322 6.
24. Gisbert JP, Fernandez-Bermejo M, Molina-Infante J, Perez-Gallardo B, Priesto-Bermejo AB, Mateos-Roderiguez JM, Robledo-Andres P, Gonzalez-Garcia G. First line triple therapy with levofloxacin for Helicobacter eradication. Aliment Pharmacol Ther 2007 26 : 495 500.
25. Uygun A, Ozel AM, Yildiz O et al. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. J Gastroenterol Hepatol 2008 23 : 42 5.
26. Gisbert JP, De la Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006 23 : 35 44.
27. Gisbert JP, Bermejo F, Castro-Fernandez M et al. H. pylori Study Group of the Asociacion Espanola de Gastroenterologia. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008 103 : 71 6.
28. Shehada S, Srugo I, Shaoul R. Failure of sequential therapy to eradicate Helicobacter pylori in previously treated subjects. Helicobacter 2007 12 : 645 7.
29. Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007 26 : 1537 42.
30. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006 24 : 1469 74.
31. Miehlke S, Schneider-Brachert W, Kirsch C et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2008 13 : 69 74.
32. Park SK, Park DI, Choi JS, Kang MS, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. The effect of probiotics on Helicobacter pylori eradication. Hepatogastroenterology 2007 54 : 2032 6.
33. Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007 137 : 812S 8S.
34. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006 23 : 1077 86.
35. Di Mario F, Aragona G, Dal Bó N et al. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment Pharmacol Ther 2006 23 : 1235 40.
36. Tursi A, Elisei W, Brandimarte G, Giorgetti GM, Modeo ME, Aiello F. Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med Sci Monit 2007 13 : CR187 190.
37. de Bortoli N, Leonardi G, Ciancia E et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 2007 102 : 951 6.
38. Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, Nista EC, Cammarota G, Gasbarrini G, Gasbarrini A. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002 97 : 2744 9.
39. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, Cammarota G, Gasbarrini G, Gasbarrini A. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2004 20 : 1181 8.
40. Tong JL, Ran ZH, Shen J et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007 25 : 155 68.
41. Kuo CJ, Guo RT, Lu IL, Liu HG, Wu SY, Ko TP, Wang AH, Liang PH. Structure-based inhibitors exhibit differential activities against Helicobacter pylori and Escherichia coli undecaprenyl pyrophosphate synthases. J Biomed Biotechnol 2008 2008 : 841312.
42. Supuran CT. Carbonic anhydrases - an overview. Curr Pharm Des 2008 14 : 603 14.
43. Nishimori I, Onishi S, Takeuchi H, Supuran CT. The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des 2008 14 : 622 30.
44. Campo SMA, Zullo A, Hassan C, Morini S. Antibiotic treatment strategies for Helicobacter pylori infection. Recent Patents Anti-Infect Drug Disc 2007 2 : 11 7.
45. Aebischer T, Schmitt A, Walduck AK, Meyer TF. Helicobacter pylori vaccine development; facing the challenge. Int J Med Microbiol 2005 295 : 343 53.
46. Arora S, Czinn SJ. Vaccination as a method of preventing Helicobacter pylori-associated gastric cancer. Cancer Epidemiol Biomarkers Prev 2005 14 : 1890 1.
47. Michetti P, Kreiss C, Kotloff KL et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999 116 : 804 12.
48. Eriksson AM, Schon KM, Lycke NY. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 2004 173 : 3310 9.